0001562180-24-004897.txt : 20240610 0001562180-24-004897.hdr.sgml : 20240610 20240610161706 ACCESSION NUMBER: 0001562180-24-004897 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Etherington Robert Dee CENTRAL INDEX KEY: 0001835330 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39834 FILM NUMBER: 241032945 MAIL ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE STREET 2: SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clene Inc. CENTRAL INDEX KEY: 0001822791 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 852828339 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 BUSINESS PHONE: 801-676-9695 MAIL ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 FORMER COMPANY: FORMER CONFORMED NAME: Chelsea Worldwide Inc. DATE OF NAME CHANGE: 20200827 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-06-07 false 0001822791 Clene Inc. CLNN 0001835330 Etherington Robert Dee 6550 SOUTH MILLROCK DRIVE SUITE G50 SALT LAKE CITY UT 84121 true true false false Chief Executive Officer false Stock Options (Right to buy) 0.37 2024-06-07 4 A false 900000.00 0.00 A 2034-06-06 Common Stock 900000.00 900000.00 D Stock Options (Right to buy) 0.37 2024-06-07 4 A false 2250000.00 0.00 A 2034-06-06 Common Stock 2250000.00 2250000.00 D This option was granted on June 7, 2024 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested This option was granted on June 7, 2024 as an option for 2,250,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs. /s/ Jerry Miraglia POA 2024-06-10